Circulation. 2003;108:2941-2948
doi: 10.1161/01.CIR.0000103683.99399.7E
doi: 10.1161/01.CIR.0000103683.99399.7E
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;108:2941.)
© 2003 American Heart Association, Inc.
AHA/ADA Consensus Statement |
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
A Consensus Statement From the American Heart Association and American Diabetes Association
Key Words: AHA Scientific Statements • thiazolidinediones • diabetes mellitus • drugs • congestive heart failure • edema • insulin
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
Diabetes is a chronic, progressively worsening disease associated with a variety of microvascular and macrovascular complications. Cardiovascular disease (CVD) is the main cause of death in these patients.1,2 During the past decade, numerous drugs have been introduced for the treatment of type 2 diabetes that, used in monotherapy or in combination therapy, are effective in lowering blood glucose to achieve glycemic goals and in reducing diabetes-related end-organ disease.
Two such drugs, rosiglitazone and pioglitazone, belong to the class called thiazolidinediones (TZDs).3 Troglitazone, the first agent of this class to be approved, was effective in controlling glycemia but was removed from the market because of serious liver toxicity. Both rosiglitazone and pioglitazone are indicated either as monotherapy or in combination with a sulfonylurea, metformin, or insulin when diet, exercise, and a single agent do not result in adequate glycemic control4 (package insert Avandia [rosiglitazone maleate; GlaxoSmithKline] and Actos5 [pioglitazone hydrochloride; Takeda Pharmaceuticals]). In addition to lowering blood glucose, both drugs may benefit cardiovascular parameters, such as lipids, blood pressure, inflammatory biomarkers, endothelial function, and fibrinolytic status.6,7
These beneficial effects of TZDs on glycemia and cardiovascular risk factors have made them attractive agents in patients with type 2 diabetes who are at high risk for CVD. There is a growing recognition, however, that edema can occur in patients treated with either drug. Because people with diabetes are at increased risk for CVD and many have preexisting heart disease, the edema that sometimes accompanies the use of a TZD can be cause for
This article has been cited by other articles:
 |
|
 |
|
  C. Nofziger and B. L. Blazer-Yost PPAR{gamma} Agonists, Modulation of Ion Transporters, and Fluid Retention J. Am. Soc. Nephrol., December 1, 2009; 20(12): 2481 - 2483. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bianchi, R. Miccoli, G. Daniele, G. Penno, and S. Del Prato Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes Diabetes Care, November 1, 2009; 32(suppl_2): S342 - S348. [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Arnold and D. L. Keller Hyperglycemia Management in Non-critically Ill Hospitalized Patients Journal of Pharmacy Practice, October 1, 2009; 22(5): 467 - 477. [Abstract] [PDF]
|
|
|
|
 |
|
 G. G. Long, V. L. Reynolds, L. W. Dochterman, and T. E. Ryan Neoplastic and Non-neoplastic Changes in F-344 Rats Treated with Naveglitazar, a {gamma}-Dominant PPAR {alpha}/{gamma} Agonist Toxicol Pathol, October 1, 2009; 37(6): 741 - 753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Raj, C. M. Stein, P. J. Saavedra, and D. M. Roden Cardiovascular Effects of Noncardiovascular Drugs Circulation, September 22, 2009; 120(12): 1123 - 1132. [Full Text] [PDF]
|
|
|
|
 |
|
 T. N. Kelly, L. A. Bazzano, V. A. Fonseca, T. K. Thethi, K. Reynolds, and J. He Systematic Review: Glucose Control and Cardiovascular Disease in Type 2 Diabetes Ann Intern Med, September 15, 2009; 151(6): 394 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S d. Vries and D. L Russell-Jones Rosiglitazone or pioglitazone in type 2 diabetes? BMJ, August 18, 2009; 339(aug18_2): b3076 - b3076. [Full Text]
|
|
|
|
 |
|
 V. Baliga and R. Sapsford Review article: Diabetes mellitus and heart failure -- an overview of epidemiology and management Diabetes and Vascular Disease Research, July 1, 2009; 6(3): 164 - 171. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Nofziger, K. K. Brown, C. D. Smith, W. Harrington, D. Murray, J. Bisi, T. T. Ashton, F. P. Maurio, K. Kalsi, T. A. West, et al. PPAR{gamma} agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line Am J Physiol Renal Physiol, July 1, 2009; 297(1): F55 - F62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Kaneda, T Shiono, Y Miyashita, S Takahashi, Y Taketani, H Domae, J Matsumi, S Mizuno, Y Minami, K Sugitatsu, et al. Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation Heart, July 1, 2009; 95(13): 1079 - 1084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Nissen Pioglitazone to Reduce Restenosis After Bare-Metal Stent Placement? J. Am. Coll. Cardiol. Intv., June 1, 2009; 2(6): 532 - 533. [Full Text] [PDF]
|
|
|
|
|
|
S. P.B. Ramirez, J. M. Albert, M. J. Blayney, F. Tentori, D. A. Goodkin, R. A. Wolfe, E. W. Young, G. R. Bailie, R. L. Pisoni, and F. K. Port Rosiglitazone Is Associated with Mortality in Chronic Hemodialysis Patients J. Am. Soc. Nephrol., May 1, 2009; 20(5): 1094 - 1101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J. Am. Coll. Cardiol., April 14, 2009; 53(15): e1 - e90. [Full Text] [PDF]
|
|
|
|
|
|
2005 WRITING COMMITTEE MEMBERS, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation Circulation, April 14, 2009; 119(14): e391 - e479. [Full Text] [PDF]
|
|
|
|
|
|
J. W. M. Cheng, S. H. Bhatt, and J. D. Goldman-Levine The Benefit and Risk of Antidiabetic Agents Used in Patients With Heart Disease Journal of Pharmacy Practice, April 1, 2009; 22(2): 179 - 193. [Abstract] [PDF]
|
|
|
|
|
|
V. Vallon, E. Hummler, T. Rieg, O. Pochynyuk, V. Bugaj, J. Schroth, G. Dechenes, B. Rossier, R. Cunard, and J. Stockand Thiazolidinedione-Induced Fluid Retention Is Independent of Collecting Duct {alpha}ENaC Activity J. Am. Soc. Nephrol., April 1, 2009; 20(4): 721 - 729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Horton Defining the role of basal and prandial insulin for optimal glycemic control. J. Am. Coll. Cardiol., February 3, 2009; 53(5 Suppl): S21 - S27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K Mcguire, R. See, S. M Abdullah, P. G Snell, J. M Mcgavock, C. R Ayers, and L. S Szczepaniak The effect of rosiglitazone on integrated cardiovascular performance, cardiac structure, function and myocardial triglyceride: trial design and rationale Diabetes and Vascular Disease Research, January 1, 2009; 6(1): 43 - 50. [Abstract] [PDF]
|
|
|
|
|
|
A. H Wu Cardiotoxic drugs: clinical monitoring and decision making Heart, November 1, 2008; 94(11): 1503 - 1509. [Full Text] [PDF]
|
|
|
|
 |
|
 U. Khanderia, R. Pop-Busui, and K. A Eagle Thiazolidinediones in Type 2 Diabetes: A Cardiology Perspective Ann. Pharmacother., October 1, 2008; 42(10): 1466 - 1474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Approaches to Treatment of Type 2 Diabetes Diabetes Care, August 1, 2008; 31(8): 1697 - 1703. [Full Text] [PDF]
|
|
|
|
 |
|
 D. F. Lehmann and B. B. Lohray A Lesson in Moderation: Applying Pharmacodynamics to Clarify the Relationship Between Thiazolidinediones and Adverse Vascular Outcomes in Type 2 Diabetes J. Clin. Pharmacol., August 1, 2008; 48(8): 999 - 1002. [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Szocs, B. Brunmair, K. Stadlbauer, P. Nowotny, L. Bauer, A. Luger, and C. Furnsinn Age-Dependent Development of Metabolic Derangement and Effects of Intervention with Pioglitazone in Zucker Diabetic Fatty Rats J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 323 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. MacDonald, M. C. Petrie, N. M. Hawkins, J. R. Petrie, M. Fisher, R. McKelvie, D. Aguilar, H. Krum, and J. J.V. McMurray Diabetes, left ventricular systolic dysfunction, and chronic heart failure Eur. Heart J., May 2, 2008; 29(10): 1224 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Z. Duan, M. G. Usher, and R. M. Mortensen Peroxisome Proliferator-Activated Receptor-{gamma}-Mediated Effects in the Vasculature Circ. Res., February 15, 2008; 102(3): 283 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Zannad, W. G. Stough, B. Pitt, J. G.F. Cleland, K. F. Adams, N. L. Geller, C. Torp-Pedersen, B.-A. Kirwan, and F. Follath Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition Eur. Heart J., February 1, 2008; 29(3): 413 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Inzucchi and D. K. McGuire New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond Circulation, January 29, 2008; 117(4): 574 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. McGuire and S. E. Inzucchi New Drugs for the Treatment of Diabetes Mellitus: Part I: Thiazolidinediones and Their Evolving Cardiovascular Implications Circulation, January 22, 2008; 117(3): 440 - 449. [Full Text] [PDF]
|
|
|
|
|
|
R. M. Witteles and M. B. Fowler Insulin-Resistant Cardiomyopathy: Clinical Evidence, Mechanisms, and Treatment Options J. Am. Coll. Cardiol., January 15, 2008; 51(2): 93 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Erdmann and R. G. Wilcox Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure Eur. Heart J., January 1, 2008; 29(1): 12 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Behshad, K. D. Cooper, and N. J. Korman A Retrospective Case Series Review of the Peroxisome Proliferator-Activated Receptor Ligand Rosiglitazone in the Treatment of Atopic Dermatitis Arch Dermatol, January 1, 2008; 144(1): 84 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sena, I. R. Rasmussen, A. R. Wende, A. P. McQueen, H. A. Theobald, N. Wilde, R. O. Pereira, S. E. Litwin, J. P. Berger, and E. D. Abel Cardiac Hypertrophy Caused by Peroxisome Proliferator- Activated Receptor-{gamma} Agonist Treatment Occurs Independently of Changes in Myocardial Insulin Signaling Endocrinology, December 1, 2007; 148(12): 6047 - 6053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E Murphy and P. T Rodgers Effects of Thiazolidinediones on Bone Loss and Fracture Ann. Pharmacother., December 1, 2007; 41(12): 2014 - 2018. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Waites, M. A. Dominick, T. P. Sanderson, and B. E. Schilling Nonclinical Safety Evaluation of Muraglitazar, a Novel PPAR{alpha}/{gamma} Agonist Toxicol. Sci., November 1, 2007; 100(1): 248 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Erdmann, B. Charbonnel, R. G. Wilcox, A. M. Skene, M. Massi-Benedetti, J. Yates, M. Tan, R. Spanheimer, E. Standl, J. A. Dormandy, et al. Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease: Data from the PROactive Study (PROactive 08) Diabetes Care, November 1, 2007; 30(11): 2773 - 2778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Odegard, S. M. Setter, and J. J. Neumiller Considerations for the Pharmacological Treatment of Diabetes in Older Adults Diabetes Spectr, October 1, 2007; 20(4): 239 - 247. [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Lincoff, K. Wolski, S. J. Nicholls, and S. E. Nissen Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials JAMA, September 12, 2007; 298(10): 1180 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Solomon and W. C. Winkelmayer Cardiovascular Risk and the Thiazolidinediones: Deja Vu All Over Again? JAMA, September 12, 2007; 298(10): 1216 - 1218. [Full Text] [PDF]
|
|
|
|
|
|
H. Bays, J. McElhattan, and B. S Bryzinski A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus Diabetes and Vascular Disease Research, September 1, 2007; 4(3): 181 - 193. [Abstract] [PDF]
|
|
|
|
|
|
J. S. Borer, H. Pouleur, E. Abadie, F. Follath, J. Wittes, M. A. Pfeffer, B. Pitt, and F. Zannad Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval Eur. Heart J., August 1, 2007; 28(15): 1904 - 1909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ashrafian, M. P. Frenneaux, and L. H. Opie Metabolic Mechanisms in Heart Failure Circulation, July 24, 2007; 116(4): 434 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. V. Leier and G. J. Haas Diabetes and Heart Failure: The Role of Thiazolidinediones in Managing These Partners in Crime J. Am. Coll. Cardiol., July 3, 2007; 50(1): 37 - 39. [Full Text] [PDF]
|
|
|
|
|
|
D. Aguilar, B. Bozkurt, A. Pritchett, N. J. Petersen, and A. Deswal The Impact of Thiazolidinedione Use on Outcomes in Ambulatory Patients With Diabetes Mellitus and Heart Failure J. Am. Coll. Cardiol., July 3, 2007; 50(1): 32 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hellmold, H. Zhang, U. Andersson, B. Blomgren, T. Holland, A.-L. Berg, M. Elebring, N. Sjogren, K. Bamberg, B. Dahl, et al. Tesaglitazar, a PPAR{alpha}/{gamma} Agonist, Induces Interstitial Mesenchymal Cell DNA Synthesis and Fibrosarcomas in Subcutaneous Tissues in Rats Toxicol. Sci., July 1, 2007; 98(1): 63 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Nissen and K. Wolski Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes N. Engl. J. Med., June 14, 2007; 356(24): 2457 - 2471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Kahn and B. Zinman Point: Recent Long-Term Clinical Studies Support an Enhanced Role for Thiazolidinediones in the Management of Type 2 Diabetes Diabetes Care, June 1, 2007; 30(6): 1672 - 1676. [Full Text] [PDF]
|
|
|
|
|
|
J. Lindenfeld and F. A. Masoudi Fluid Retention With Thiazolidinediones: Does the Mechanism Influence the Outcome? J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1705 - 1707. [Full Text] [PDF]
|
|
|
|
|
|
H. J. Dargie, P. R. Hildebrandt, G. A.J. Riegger, J. J.V. McMurray, S. O. McMorn, J. N. Roberts, A. Zambanini, and J. P.H. Wilding A Randomized, Placebo-Controlled Trial Assessing the Effects of Rosiglitazone on Echocardiographic Function and Cardiac Status in Type 2 Diabetic Patients With New York Heart Association Functional Class I or II Heart Failure J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1696 - 1704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Brown and J. Plutzky Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets Circulation, January 30, 2007; 115(4): 518 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-K. Chiang, T.-I. Ho, Y.-S. Peng, S.-P. Hsu, M.-F. Pai, S.-Y. Yang, K.-Y. Hung, and K.-D. Wu Rosiglitazone in Diabetes Control in Hemodialysis Patients With and Without Viral Hepatitis Infection: Effectiveness and side effects Diabetes Care, January 1, 2007; 30(1): 3 - 7. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B Patle, J. A De Lemos, K. L Wyne, and D. K McGuire Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPAR{gamma} agonism Diabetes and Vascular Disease Research, September 1, 2006; 3(2): 65 - 71. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Allen, F. Zhang, S. A. Moodie, L. E. Clemens, A. Smith, F. Gregoire, A. Bell, G. E.O. Muscat, and T. A. Gustafson Halofenate Is a Selective Peroxisome Proliferator-Activated Receptor {gamma} Modulator With Antidiabetic Activity Diabetes, September 1, 2006; 55(9): 2523 - 2533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Sotiropoulos, A. Clermont, Y. Yasuda, C. Rask-Madsen, M. Mastumoto, J. Takahashi, K. Della Vecchia, T. Kondo, L. P. Aiello, and G. L. King Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPAR{gamma} agonist's effects on edema and weight gain FASEB J, June 1, 2006; 20(8): 1203 - 1205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Rizza, R. Henry, and R. Kahn Commentary on the Results and Clinical Implications of the PROactive Study Clin. Diabetes, April 1, 2006; 24(2): 66 - 68. [Full Text] [PDF]
|
|
|
|
|
|
U. Campia, L. A. Matuskey, and J. A. Panza Peroxisome Proliferator-Activated Receptor-{gamma} Activation With Pioglitazone Improves Endothelium-Dependent Dilation in Nondiabetic Patients With Major Cardiovascular Risk Factors Circulation, February 14, 2006; 113(6): 867 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Cekmen, M. Cesur, R. Cetinbas, P. Bedel, and O. Erdemli Acute Pulmonary Edema Due to Rosiglitazone Use in a Patient With Diabetes Mellitus J Intensive Care Med, January 1, 2006; 21(1): 47 - 50. [Abstract] [PDF]
|
|
|
|
|
|
R. Rizza, R. Henry, and R. Kahn Commentary on the Results and Clinical Implications of the PROactive Study Diabetes Care, December 1, 2005; 28(12): 2965 - 2967. [Full Text] [PDF]
|
|
|
|
|
|
M. Malone Medications Associated with Weight Gain Ann. Pharmacother., December 1, 2005; 39(12): 2046 - 2054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Nissen, K. Wolski, and E. J. Topol Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus JAMA, November 23, 2005; 294(20): 2581 - 2586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zhang, A. Zhang, D.E. Kohan, R.D. Nelson, F.J. Gonzales, T. Yang, C. Schmidt-Lucke, L. Rossig, S. Fichtlscherer, M. Vasa, et al. Edema and Congestive Heart Failure from Thiazolidone Insulin Sensitizers--Excess Sodium Reabsoption in the Collecting Duct: Collecting Duct-Specific Deletion of Peroxisome Proliferator-Activated Receptor {gamma} Blocks Thiazolidinedione-Induced Fluid Retention. Proc Nat Acad Sci U S A 102: 9406-9411, 2005 J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3139 - 3142. [Full Text] [PDF]
|
|
|
|
|
|
S. Fiorucci, G. Rizzo, E. Antonelli, B. Renga, A. Mencarelli, L. Riccardi, A. Morelli, M. Pruzanski, and R. Pellicciari Cross-Talk between Farnesoid-X-Receptor (FXR) and Peroxisome Proliferator-Activated Receptor {gamma} Contributes to the Antifibrotic Activity of FXR Ligands in Rodent Models of Liver Cirrhosis J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 58 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Developed in Collaboration With the American Colle, Endorsed by the Heart Rhythm Society, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) J. Am. Coll. Cardiol., September 20, 2005; 46(6): 1116 - 1143. [Full Text] [PDF]
|
|
|
|
|
|
S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society Circulation, September 20, 2005; 112(12): 1825 - 1852. [Full Text] [PDF]
|
|
|
|
|
|
S. Z. Duan, C. Y. Ivashchenko, M. W. Russell, D. S. Milstone, and R. M. Mortensen Cardiomyocyte-Specific Knockout and Agonist of Peroxisome Proliferator-Activated Receptor-{gamma} Both Induce Cardiac Hypertrophy in Mice Circ. Res., August 19, 2005; 97(4): 372 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Staels and J.-C. Fruchart Therapeutic Roles of Peroxisome Proliferator-Activated Receptor Agonists Diabetes, August 1, 2005; 54(8): 2460 - 2470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Inzucchi, F. A. Masoudi, Y. Wang, M. Kosiborod, J. M. Foody, J. F. Setaro, E. P. Havranek, and H. M. Krumholz Insulin-Sensitizing Antihyperglycemic Drugs and Mortality After Acute Myocardial Infarction: Insights from the National Heart Care Project Diabetes Care, July 1, 2005; 28(7): 1680 - 1689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zhang, A. Zhang, D. E. Kohan, R. D. Nelson, F. J. Gonzalez, and T. Yang Collecting duct-specific deletion of peroxisome proliferator-activated receptor {gamma} blocks thiazolidinedione-induced fluid retention PNAS, June 28, 2005; 102(26): 9406 - 9411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Maaravi and J. Stessman Mild, Reversible Pancytopenia Induced by Rosiglitazone Diabetes Care, June 1, 2005; 28(6): 1536 - 1536. [Full Text] [PDF]
|
|
|
|
|
|
C. Patel, K. L Wyne, and D. K McGuire Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? Diabetes and Vascular Disease Research, May 1, 2005; 2(2): 61 - 66. [Abstract] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden The European Association for the Study of Diabetes Diabetes Care, May 1, 2005; 28(5): 1250 - 1257. [Full Text] [PDF]
|
|
|
|
|
|
B. Kimmel and S. E. Inzucchi Oral Agents for Type 2 Diabetes: An Update Clin. Diabetes, April 1, 2005; 23(2): 64 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Schiffrin Peroxisome proliferator-activated receptors and cardiovascular remodeling Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1037 - H1043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Masoudi, S. E. Inzucchi, Y. Wang, E. P. Havranek, J. M. Foody, and H. M. Krumholz Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study Circulation, February 8, 2005; 111(5): 583 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y.Y. Cheng and I. G. Fantus Oral antihyperglycemic therapy for type 2 diabetes mellitus Can. Med. Assoc. J., January 18, 2005; 172(2): 213 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. V. Erbe, S. Wang, Y.-L. Zhang, K. Harding, L. Kung, M. Tam, L. Stolz, Y. Xing, S. Furey, A. Qadri, et al. Ertiprotafib Improves Glycemic Control and Lowers Lipids via Multiple Mechanisms Mol. Pharmacol., January 1, 2005; 67(1): 69 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J.V. McMurray and M. A. Pfeffer The year in heart failure J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2398 - 2405. [Full Text] [PDF]
|
|
|
|
|
|
Z. T. Bloomgarden Inpatient Diabetes Control: Rationale Diabetes Care, August 1, 2004; 27(8): 2074 - 2080. [Full Text] [PDF]
|
|
|
|
 |
|
 J. P.H. van Wijk and T. J. Rabelink PPAR-{gamma} Agonists: Shifting Attention from the Belly to the Heart? Arterioscler Thromb Vasc Biol, May 1, 2004; 24(5): 798 - 800. [Full Text]
|
|
|
|
 |
|
 Consensus Statement on TZD Hypoglycemic Agents and Heart Failure Journal Watch (General), January 30, 2004; 2004(130): 1 - 1. [Full Text]
|
|